- Page 1 and 2:
Health Technology Assessment 2006;
- Page 3 and 4:
The clinical and cost-effectiveness
- Page 5 and 6:
Objectives: To provide an update re
- Page 7 and 8:
List of abbreviations .............
- Page 9 and 10:
AChEI acetylcholinesterase inhibito
- Page 11 and 12:
Epidemiology and background Alzheim
- Page 13:
Galantamine Five published economic
- Page 17 and 18:
Description of underlying health pr
- Page 19 and 20:
TABLE 1 Estimated prevalence of AD
- Page 21 and 22:
as one component of their care. A n
- Page 23 and 24:
The a priori methods used for syste
- Page 25:
Data synthesis Data were synthesise
- Page 28 and 29:
14 Clinical effectiveness TABLE 3 C
- Page 30 and 31:
16 Clinical effectiveness TABLE 3 C
- Page 32 and 33:
18 Clinical effectiveness particula
- Page 34 and 35:
20 Clinical effectiveness Compariso
- Page 36 and 37:
22 Clinical effectiveness TABLE 6 M
- Page 38 and 39:
24 Clinical effectiveness donepezil
- Page 40 and 41:
26 Clinical effectiveness Compariso
- Page 42 and 43:
28 Clinical effectiveness Compariso
- Page 44 and 45:
30 Clinical effectiveness Compariso
- Page 46 and 47:
32 Clinical effectiveness DAD The D
- Page 48 and 49:
34 Clinical effectiveness clinical
- Page 50 and 51:
36 Clinical effectiveness TABLE 10
- Page 52 and 53:
38 Clinical effectiveness TABLE 10
- Page 54 and 55:
40 Clinical effectiveness statistic
- Page 56 and 57:
42 Clinical effectiveness TABLE 14
- Page 58 and 59:
44 Clinical effectiveness Compariso
- Page 60 and 61:
46 Clinical effectiveness Summary:
- Page 62 and 63:
48 Clinical effectiveness differenc
- Page 64 and 65:
50 Clinical effectiveness TABLE 22
- Page 66 and 67:
52 Clinical effectiveness This appe
- Page 68 and 69:
54 Clinical effectiveness TABLE 24
- Page 70 and 71:
56 Clinical effectiveness TABLE 26
- Page 72 and 73:
58 Clinical effectiveness Compariso
- Page 74 and 75:
60 Clinical effectiveness TABLE 28
- Page 76 and 77:
62 Clinical effectiveness placebo [
- Page 78 and 79:
64 Clinical effectiveness TABLE 31
- Page 80 and 81:
66 Clinical effectiveness (24 mg/da
- Page 82 and 83:
68 Clinical effectiveness TABLE 35
- Page 84 and 85:
70 Clinical effectiveness ● One R
- Page 86 and 87:
72 Clinical effectiveness by the pa
- Page 88 and 89:
74 Clinical effectiveness TABLE 42
- Page 90 and 91:
76 Clinical effectiveness TABLE 46
- Page 92 and 93:
78 Clinical effectiveness donepezil
- Page 94 and 95:
80 Evidence from systematic reviews
- Page 96 and 97:
82 Economic analysis TABLE 48 Chara
- Page 98 and 99:
84 TABLE 49 Economic analysis Outli
- Page 100 and 101:
86 Economic analysis The UK study r
- Page 102 and 103:
88 Economic analysis The AD2000 stu
- Page 104 and 105:
90 Economic analysis term). Where w
- Page 106 and 107:
92 Economic analysis published econ
- Page 108 and 109:
94 Economic analysis Fenn and Gray
- Page 110 and 111:
96 Economic analysis one another. W
- Page 112 and 113:
98 Economic analysis outcomes: (1)
- Page 114 and 115:
100 Economic analysis respond to ga
- Page 116 and 117:
102 Economic analysis donepezil, ri
- Page 118 and 119:
104 Economic analysis of this study
- Page 120 and 121:
106 Economic analysis independent,
- Page 122 and 123:
108 Economic analysis classificatio
- Page 124 and 125:
110 Economic analysis survey studie
- Page 126 and 127:
112 Economic analysis vascular deme
- Page 128 and 129:
114 Economic analysis Livingston an
- Page 130 and 131:
116 Economic analysis sensitive to
- Page 132 and 133: 118 Economic analysis Neumann and c
- Page 134 and 135: 120 Economic analysis The model str
- Page 136 and 137: 122 Economic analysis CEA, given th
- Page 138 and 139: 124 Economic analysis TABLE 70 Key
- Page 140 and 141: 126 Economic analysis TABLE 73 Prof
- Page 142 and 143: 128 Economic analysis Probability o
- Page 144 and 145: 130 Economic analysis Results are s
- Page 146 and 147: 132 Economic analysis 4. The model
- Page 148 and 149: 134 Economic analysis perspective e
- Page 150 and 151: 136 Economic analysis indicating th
- Page 153: Ongoing research, with relevance to
- Page 157: The increasing numbers of the very
- Page 160 and 161: 146 Discussion and conclusions dose
- Page 162 and 163: 148 Discussion and conclusions effo
- Page 164 and 165: 150 Discussion and conclusions Stre
- Page 167 and 168: 1. Clegg A, Bryant J, Nicholson T,
- Page 169 and 170: placebo-controlled study of donepez
- Page 171 and 172: 94. Brooks E, Deal L. The effect of
- Page 173 and 174: of memantine in patients with moder
- Page 175: This version of HTA monograph volum
- Page 179 and 180: 376 Health Technology Assessment Pr
- Page 181: 378 Health Technology Assessment Pr